Between 2024 and 2028, antiinfective medicine sales in Canada are forecasted to slightly increase from $43.2 to $44 USD PPP per capita. This reflects a modest upward trend, with year-on-year growth expected to hover around 0.7% annually. In comparison, 2023's data positions the sales figure at a slightly lower level, marking a stable but slow growth trajectory. The five-year compound annual growth rate (CAGR) is projected to be approximately 0.35%.
Future trends to watch for:
- Potential regulatory changes impacting medicine prices and accessibility.
- Advancements in biotechnology that might introduce new antiinfective drugs.
- Public health strategies and their impact on demand.
